Patients with type 2 diabetes or metabolic syndrome often have mixed dyslipidemia accompanied by cardiovascular risk factors. Dyslipidemia in the patient with type 2 diabetes contributes to atherosclerotic risk and coronary heart disease. There were several large meta- analysises that provide strong evidence of benefit of statin in CV risk patients, with a little evidence of any hazard. A large meta-analysis from the Cholesterol Trialists' Collaboration (CTT) included 21 studies with more than 130,000 patients, comparing statins vs placebo controls, and another five studies, with approximately 40,000 patients, examining different statin doses. As a result, there was a 22% proportional reduction in the risk of major vascular events for each 1 mmol/L reduction in LDL cholesterol. It implies that 2-3 mmol/L reduction would reduce risk of vascular events by about 40-50%. Additional reductions in LDL cholesterol with more intensive therapy further reduce the incidence of these major vascular events and do not increase the risk of developing cancer and myopathy (except SEARCH and A to Z trial). Recently, a meta-analysis of the high-profile statin trials testing an increase of the risk of diabetes issued on the Journal of the American Medical Association. The idea for this meta-analysis began two years ago when the signal for diabetes risk was observed in JUPITER trial. The group later performed an analysis of some of the early statin trials comparing the lipid-lowering drugs with placebo in 90,000 individuals and observed a significant 9% increase in the risk of diabetes mellitus. The trials included in this newest meta-analysis were five trials including PROVE-IT, A to Z, TNT, IDEAL, and SEARCH, that together included 32,752 patients without diabetes at baseline. In conclusion, 1,449 patients treated with high-dose statin therapy developed diabetes compared with 1300 patients assigned to moderate- dose statin therapy. The odds ratio for new-onset diabetes was 1.12 (95% CI 1.04-1.22). Regarding the benefit, 3,134 patients treated with high-dose statin therapy and 3,550 patients treated with moderate-dose therapy had a cardiovascular event and the relative reduction was 16%. Therefore, we should see an off-target effect. Right now we have no obvious mechanism on the risk of diabetes mellitus by statins. However, the benefit of statins for reducing important macrovascular events is so overwhelming that the balance is clearly on the side of benefit. While monitoring HbA1c levels when treating patients with high-dose statin therapy, we clinicians should continue the stain treatment, especially for the patients at high risk for cardiovascular events.